Investment Rating - The investment rating for the company is "Buy" with a previous rating of "Buy" as well [1] Core Views - The company reported a revenue of 391 million RMB for the first three quarters of 2025, representing a year-on-year growth of 17.65%. The net profit attributable to the parent company was 61.98 million RMB, showing a significant increase of 623.19% year-on-year [4] - The company is experiencing rapid growth in its ultrasonic bone knife business and has begun to make breakthroughs in its international operations, leading to a positive outlook for future development [4][6] Summary by Relevant Sections Financial Performance - The company adjusted its profit forecast, expecting net profits for 2025-2027 to be 115 million, 179 million, and 259 million RMB respectively, with corresponding EPS of 0.34, 0.54, and 0.78 RMB. The current stock price corresponds to PE ratios of 55.7, 35.7, and 24.7 times for the respective years [6][8] - The company’s revenue for Q3 was 142 million RMB, a year-on-year increase of 17.44%, with a net profit of 25.38 million RMB, up 268.13% year-on-year [9] Business Segments - The ultrasonic bone knife business showed impressive performance, with revenue of 115 million RMB in the first three quarters, a growth of 52.21% year-on-year. The company has completed its performance commitments for 2025 [9] - The international business is progressing rapidly, with the French subsidiary Implanet achieving revenue of 2.92 million euros in Q3, a growth of 26.37%, and the US market contributing 1.06 million euros, up 22.21% [9] Future Outlook - The company’s innovative products are entering a harvest phase, with recent approvals for new products enhancing its domestic product line. This is expected to stabilize domestic business growth [9]

Core Viewpoint - Q3 performance met expectations, with stable growth in domestic terminal surgeries and sales, and continuous performance growth in international business, especially in the US market [1][4] - The company is expected to achieve steady growth in domestic spinal business and continued expansion in ultrasound bone knife and overseas business in Q4 and next year [1][5] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 391 million yuan (+17.65%) and a net profit attributable to shareholders of 62 million yuan (+623.19%), with a non-recurring net profit of 49 million yuan (+1737.69%) [2][4] - Q3 single-quarter revenue was 142 million yuan (+17.44%) and net profit attributable to shareholders was 25 million yuan (+268.13%) [4] - The company’s gross profit margin improved to 74.31% (+4.63 percentage points) [6] Business Growth - The domestic spinal business is expected to return to steady growth following the clearance of the impact from spinal centralized procurement [5][7] - The ultrasound bone knife business is anticipated to grow rapidly as its penetration rate in the domestic market is currently low [5][7] - The company’s overseas revenue from the French subsidiary Implanet reached 291.59 million euros, with the US market becoming the largest market for Implanet [5] Future Outlook - The company is projected to achieve revenues of 545 million yuan, 675 million yuan, and 840 million yuan from 2025 to 2027, with year-on-year growth rates of 20.2%, 23.8%, and 24.4% respectively [7] - Net profit attributable to shareholders is expected to reach 90 million yuan, 130 million yuan, and 167 million yuan during the same period, with significant growth rates [7]

Investment Rating - The industry investment rating is maintained as "Outperform the Market" [2][57]. Core Insights - The orthopedic consumables sector has shown continuous improvement in performance during the first three quarters of 2025, with a positive trend in overseas expansion [3][10]. - The overall revenue of the orthopedic consumables sector increased by 17% year-on-year for Q1-Q3 2025, with net profit attributable to shareholders rising by 81% [5][10]. - The gross profit margin for the sector improved to 66% in Q1-Q3 2025, reflecting effective cost control and optimization [4][10]. - The trend of companies actively pursuing international markets is expected to become a significant growth driver [10][27]. Summary by Sections 1. Orthopedic Consumables Q3 2025 Report Analysis - The orthopedic consumables sector's revenue for Q1-Q3 2025 reached 49.18 billion, with a year-on-year growth of 17% [9]. - The gross profit margin for Q3 2025 was reported at 67%, an increase of 2.06 percentage points compared to the previous year [10]. - The net profit attributable to shareholders for Q3 2025 doubled year-on-year, indicating significant performance improvement [10]. 2. Segment Analysis - The joint business segment has seen stable growth due to the continuation of centralized procurement and an increase in both volume and price for leading companies [19][24]. - The spinal segment is experiencing a steady execution of centralized procurement, with leading domestic brands increasing their market share [25]. - The trend of domestic companies expanding overseas is gaining momentum, with a focus on product innovation and international development [27][29]. 3. Related Company Q3 Report Summary - Major companies in the sector, such as Dabo Medical, Weigao Orthopedics, and Spring Medical, have shown strong revenue growth and profitability improvements in Q3 2025 [12][41][45]. - Dabo Medical reported a revenue of 18.76 billion, up 22.69% year-on-year, with a net profit of 4.25 billion, reflecting a 77.03% increase [45]. - Spring Medical achieved a remarkable revenue growth of 109.5% in Q3 2025, turning a previous loss into a profit of 770.6 million [33].

Core Points - The company held its fifth extraordinary general meeting of shareholders on November 7, 2025, with no resolutions being rejected [2][4] - All proposed resolutions were approved during the meeting, including a resolution to provide guarantees for a controlling company and to reappoint the accounting firm [4][5] - The meeting was presided over by the chairman, Michael MingYan Liu, and attended by all nine current directors and key executives [3][4] Fundraising Information - The company successfully raised a total of RMB 1,075,950,160.00 from its initial public offering (IPO) in 2020, with a net amount of RMB 978,057,381.28 after deducting issuance costs [10] - In a subsequent issuance, the company raised RMB 213,999,988.12, with a net amount of RMB 203,920,127.60 after related expenses [12] - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [14] Account Cancellation - The company decided to cancel a special fundraising account at Shanghai Pudong Development Bank due to the completion of the use of excess funds from the IPO [15] - The cancellation of the account has been completed, and the corresponding regulatory agreement has been terminated [15]

Fundraising Overview - The company successfully completed its initial public offering (IPO) on March 12, 2020, raising a total of RMB 1,075,950,160.00, with a net amount of RMB 978,057,381.28 after deducting issuance costs [2] - The company was also approved to issue shares for asset acquisition and raise matching funds, totaling RMB 213,999,988.12, with a net amount of RMB 203,920,127.60 after related expenses [3] Fund Management - The company has established a dedicated account for fundraising, adhering to regulatory requirements and ensuring strict supervision of fund usage [5] - The company has signed a tripartite supervision agreement with its financial advisor and the bank holding the funds to ensure proper management [4] Account Cancellation - The company has decided to cancel a specific fundraising account at Shanghai Pudong Development Bank, as the excess funds from the IPO have been fully utilized [7] - The cancellation process has been completed, and the corresponding supervision agreement has been terminated [7]

Group 1 - The company announced the completion of the use of over-raised funds from its initial public offering, which were stored in a dedicated account at Shanghai Pudong Development Bank [1] - The dedicated fundraising account will be canceled to facilitate the management of the company's financial accounts [1] - The company has completed the cancellation procedures for the dedicated fundraising account and terminated the corresponding storage supervision agreement with the sponsor and the bank [1]

证券代码：688085 证券简称：三友医疗 公告编号：2025-086 上海三友医疗器械股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）首次公开发行股票 经上海证券交易所科创板上市委员会 2020 年 1 月 8 日审核同意，并经中国 证券监督管理委员会于 2020 年 3 月 12 日《关于同意上海三友医疗器械股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕402 号）同意注册，公 司获准向社会公开发行人民币普通股 51,333,500 股，每股面值人民币 1.00 元， 每股发行价为人民币 20.96 元，合计募集资金人民币 1,075,950,160.00 元，扣除 各 项 发 行 费 用 （ 不 含 税 ） 人 民 币 97,892,778.72 元 后 ， 募 集 资 金 净 额 为 978,057,381.28 元。上述募集资金已全部到位，并由立信会计师事务所（特殊普 通合伙）验证并出具"信会师报字[2020]第 ZA ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-085 上海三友医疗器械股份有限公司 2025年第五次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 7 日 （二） 股东会召开的地点：上海市嘉定区嘉定工业区汇荣路 385 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 59 | | --- | --- | | 普通股股东人数 | 59 | | 2、出席会议的股东所持有的表决权数量 | 87,617,658 | | 普通股股东所持有表决权数量 | 87,617,658 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 26.2751 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 26.2751 | （四） 表 ...

北京市嘉源律师事务所 关于上海三友医疗器械股份有限公司 2025 年第五次临时股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 源 酒 中 新 事 分 P A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海三友医疗器械股份有限公司 北京市嘉源律师事务所 关于上海三友医疗器械股份有限公司 2025年第五次临时股东会的 法律意见书 嘉源(2025)-04-793 北京市嘉源律师事务所(以下简称"本所")接受上海三友医疗器械股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《上 海三友医疗器械股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司 2025年第五次临时股东会(以下简称"本次股东会")进行见 证,并依法出具本法律 ...

Macroeconomic News - The State Council announced the holiday schedule for 2026, including a 3-day break for New Year's, a 9-day break for Spring Festival, and a 5-day break for Labor Day [2] - The Ministry of Commerce responded to questions regarding ASML, stating that the Dutch government interfered with the company's internal affairs and that ASML (Netherlands) announced on October 26 to stop supplying wafers to ASML (China), causing disruptions in the global semiconductor supply chain [2] - The People's Bank of China will conduct a 700 billion yuan reverse repurchase operation on November 5, 2025, to maintain liquidity in the banking system [3] - In October, the central bank resumed trading of government bonds, with a net injection of 20 billion yuan [3] - The U.S. Senate failed to pass a temporary funding bill again, leading to a record government shutdown [3] Company News - Fuyao Glass announced a change in its legal representative from Cao Dewang to his son, Cao Hui [8] - Industrial Fulian reported a cumulative repurchase of 0.04% of its shares, amounting to 147 million yuan as of October 31 [9] - True Love Home announced plans for a change in control, leading to a stock suspension [10] - ST Wanfang disclosed that its stock price volatility was mainly due to market speculation regarding a change in control [11] - Siwei Liekong announced the dismissal of Deputy General Manager Zhao Jianzhou, who is under investigation [12] - Haichuang Pharmaceutical completed the enrollment of the first batch of participants in the Phase II clinical trial for its drug HP515, targeting metabolic-associated fatty liver disease [13] - Midea Group has repurchased a total of 9.575 billion yuan of its A-shares [14] - Tianpu Co. completed the transfer of shares with its controlling shareholder and a related party [15] - Baili Tianheng's innovative biopharmaceutical T-Bren (HER2ADC) has been included in the list of breakthrough therapy varieties [16] - Redik announced plans to acquire a 20.41% stake in robotics and brain-computer interface company Aoyi Technology for 160 million yuan [17] Global Market - U.S. stock indices collectively fell, with the Nasdaq down 2.04%, S&P 500 down 1.17%, and Dow Jones down 0.53% [18] - Major technology stocks declined, with Intel dropping over 6%, Tesla over 5%, and Nvidia nearly 4% [18] - Cryptocurrency stocks saw significant declines, with Bakkt down nearly 20% and Galaxy Digital down over 10% [18] - European major indices mostly closed lower, with Germany's DAX30 down 0.6% [18] Investment Opportunities - The robot industry in China saw a revenue increase of 29.5% year-on-year in the first three quarters of this year, with industrial robot production reaching 595,000 units and service robot production reaching 13.5 million units, surpassing the total production for 2024 [23] - Dongfang Securities believes that the industry is expected to enter a mass production phase next year, benefiting component manufacturers with excellent manufacturing and management capabilities [24] - SK Hynix announced the development of new storage products, including AI-DRAM and AI-NAND, and is deepening partnerships to advance AI manufacturing technology [25] - Guotai Junan Securities noted that the storage industry has entered a new upcycle, driven by the increasing demand for memory capacity due to AI model training and inference [25]